Table 3 Sensitivity analysis of the association between MTHFR A1298C and CHD by omitting a single study each time

1.11

0.90–1.38

1.28

0.86–1.91

1.23

0.96–1.59

1.04

0.79–1.37

1.08

0.82–1.43

1.35

1.07–1.71

1.16

0.95–1.41

1.39

0.97–2.00

1.28

1.00–1.63

1.07

0.82–1.41

1.13

0.86–1.48

1.40

1.12–1.76

1.16

0.94–1.42

1.37

0.92–2.05

1.21

0.92–1.57

1.11

0.85–1.44

1.15

0.87–1.50

1.41

1.10–1.80

1.17

0.95–1.43

1.43

0.99–2.06

1.28

1.00–1.64

1.10

0.84–1.43

1.15

0.88–1.50

1.43

1.13–1.80

1.16

0.94–1.42

1.39

0.94–2.06

1.27

0.98–1.64

1.10

0.83–1.43

1.14

0.86–1.50

1.43

1.13–1.81

1.14

0.91–1.42

1.33

0.88–2.01

1.26

0.97–1.63

1.06

0.79–1.43

1.11

0.82–1.50

1.40

1.10–1.78

1.15

0.94–1.41

1.36

0.93–1.99

1.26

0.99–1.61

1.09

0.83–1.42

1.13

0.87–1.49

1.39

1.11–1.75

1.12

0.91–1.39

1.33

0.90–1.98

1.27

0.99–1.63

1.04

0.79–1.37

1.09

0.82–1.44

1.39

1.11–1.76

1.12

0.91–1.38

1.27

0.86–1.89

1.19

0.92–1.53

1.07

0.81–1.41

1.10

0.83–1.46

1.33

1.05–1.68

1.14

0.93–1.41

1.38

0.94–2.03

1.28

1.00–1.65

1.06

0.80–1.40

1.11

0.84–1.47

1.41

1.12–1.78

1.08

0.89–1.32

1.23

0.84–1.81

1.23

0.95–1.59

1.02

0.78–1.33

1.05

0.81–1.37

1.31

1.03–1.66

1.15

0.94–1.40

1.30

0.89–1.89

1.23

0.97–1.57

1.10

0.86–1.41

1.14

0.88–1.48

1.36

1.09–1.71

1.12

0.91–1.39

1.37

0.94–2.01

1.29

1.01–1.65

1.03

0.78–1.36

1.08

0.82–1.43

1.41

1.12–1.77

1.09

0.89–1.33

1.24

0.85–1.82

1.26

0.98–1.62

1.00

0.78–1.29

1.04

0.80–1.35

1.35

1.07–1.70

1.09

0.89–1.33

1.33

0.92–1.92

1.25

0.98–1.60

1.00

0.78–1.30

1.05

0.81–1.37

1.38

1.10–1.73

1.06

0.89–1.26

1.21

0.86–1.71

1.28

0.99–1.65

0.99

0.78–1.25

1.02

0.80–1.29

1.28

1.01–1.63

1.13

0.92–1.37

1.33

0.92–1.92

1.25

0.98–1.60

1.05

0.81–1.36

1.10

0.84–1.43

1.38

1.10–1.73